Stocks
Funds
Screener
Sectors
Watchlists
TXMD

TXMD - TherapeuticsMD Inc Stock Price, Fair Value and News

$2.14-0.28 (-11.57%)
Market Closed

42/100

TXMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

TXMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.29

Target 3M

$2.53

Target 6M

$2.45

TXMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TXMD Price Action

Last 7 days

-14.1%

Last 30 days

27.4%

Last 90 days

72.6%

Trailing 12 Months

96.3%

TXMD RSI Chart

TXMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TXMD Valuation

Market Cap

24.8M

Price/Earnings (Trailing)

82.02

Price/Sales (Trailing)

8.86

EV/EBITDA

44.47

Price/Free Cashflow

11.82

TXMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.29

Target 3M

$2.53

Target 6M

$2.45

TXMD Fundamentals

TXMD Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

43.33%

Rev. Growth (Qtr)

-17.65%

TXMD Earnings

Earnings (TTM)

302.0K

Earnings Growth (Yr)

124.96%

Earnings Growth (Qtr)

-72.41%

TXMD Profitability

EBT Margin

0.36%

Return on Equity

1.1%

Return on Assets

0.78%

Free Cashflow Yield

8.46%

TXMD Investor Care

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

0.02

TXMD Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.8M2.6M2.8M0
20241.4M1.5M1.6M1.8M
202352.8M35.6M18.5M1.3M
202267.8M45.1M57.5M70.0M
202172.5M84.8M90.9M87.0M
202058.0M62.6M58.2M64.9M
201916.3M18.6M38.8M49.6M
201816.6M16.1M15.1M16.1M
201718.4M18.3M17.1M16.8M
201620.6M20.2M20.5M19.4M
201516.7M17.8M18.8M20.1M
201410.3M11.7M13.6M15.0M
201305.5M7.1M8.8M
20122.3M2.6M3.1M3.8M
20111.5M1.7M1.9M2.1M
20100001.2M
TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
 WEBSITEtherapeuticsmd.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES1

TherapeuticsMD Inc Frequently Asked Questions


TXMD is the stock ticker symbol of TherapeuticsMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of TherapeuticsMD Inc is 24.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TXMD's fair value in chart for subscribers.

The fair value guage provides a quick view whether TXMD is over valued or under valued. Whether TherapeuticsMD Inc is cheap or expensive depends on the assumptions which impact TherapeuticsMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXMD.

As of Wed Jan 28 2026, TXMD's PE ratio (Price to Earnings) is 82.02 and Price to Sales (PS) ratio is 8.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXMD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, TherapeuticsMD Inc has provided -0.401 (multiply by 100 for percentage) rate of return.